Aim: This study aimed to examine gender differences in the prevalence of COPD as detected during a public awareness programme with spirometry measurement in screening for COPD in a self-selected population. Method: A series of public education events were held in selected locations in Singapore from 2010 to 2011 on the causes, symptoms and risk of developing COPD. After completing the risk assessment questionnaire, participants were invited to undergo spirometry. Results: 928 unique subjects participated in the public education events. The mean age was 52 years, 63% were men. 81 (8.7%) had clinically significant airflow obstruction (FEV 1/FVC<0.7). Of these, 33 subjects (41%) had mild COPD, (FEV 1 > 80% pred), 36 (44%) had moderate COPD (FEV1<80% but >50%pred) and the remaining had severe COPD. There were no significant differences between the proportion of male and female subjects with COPD (8.9% and 8.4% respectively). The proportion of smokers/ex-smokers among men was significantly higher than among women (81% vs 30% respectively [p<0.001]). The smoking and age-group adjusted prevalence of COPD among males and females was 6.9% and 8.2% respectively. Conclusion: In spite of significantly lower self-declared smoking rates among women, COPD was more prevalent in women as compared to men who were screened during the COPD public awareness programme in our study population. We postulate that this may be due to a general under-reporting of the smoking rates among women, or that women are more susceptible to smoking-related lung damage. Aim: The purpose of this study was to determine the relationship between pain and the six-minute walk distance test (6MWT), physical activity (assessed by 3D accelerometry), and concentric knee extensor torque in people with COPD. Methods: Twenty-six people with moderate to severe COPD completed the McGill Pain Questionnaire (MPQ), the Brief Pain Inventory (BPI), the Short Form-36 (SF-36), and a form to list medications and co-morbidities. After spirometry, participants performed the 6MWT. Physical activity was monitored for two days using a DynaPort MiniMod Monitor 3D accelerometer. At least 3 days after the 6MWT, maximal and fatiguing concentric contractions of the knee extensors were assessed on a Biodex dynamometer. Correlations were performed between pain severity and 6MWT, physical activity, and knee extensor torque. These physical performance measures were compared in COPD patients with the most severe pain versus those with moderate to no pain.
IPCRG13-1075 SUPPORTED SELF-MANAGEMENT FOR PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AT, OR SHORTLY AFTER, DISCHARGE FROM HOSPITAL: A SYSTEMATIC REVIEW OF THE EVIDENCE FOR EFFECTIVENESS AND COST-EFFECTIVENESS
Medical Director, 5 Medical Services, 6 Marketing, Cipla Limited, Mumbai, 7 Director, Chest Research Foundation, Pune, India Aim: We aimed to explore the association between OADs and cataract in a large, nationwide, cross sectional, observational study amongst primary care physicians of India. Methods: 12,000 randomly selected primary care physicians from 880 cities and towns were invited to participate in a 1-day point prevalence study. Each doctor kept a record of all symptoms and diagnosis of patients who visited them on 1st Feb '11, on a modified ICD-10 classification questionnaire. Quality checked data entered into Epi-info software was analyzed using simple descriptive statistics. Chi square test was used to study associations between OADs and cataract. Results: 7400 doctors provided data on 204,912 patients (M: 54.1%; F: 45.9%). 16075 (7.8%) patients had OADs and 1086 (0.5%) had cataract. Doctor-diagnosed OADs were strongly associated with cataract [OR: 3.87 (3.37, 4.45 
University of Groningen, Groningen, Netherlands
Aim: Previous studies showed that many patients with asthma ignore symptoms and overestimate the extent to which their disease is controlled, accepting a lower quality of life. We report data from the largest and most recent European survey of patient attitudes to asthma and its management, to assess whether the discrepancy between perceived and guideline-defined control has improved. Methods: Online surveys were conducted with 8000 patients with asthma (aged 18-50 years, >2 prescriptions in the last 2 years) from 11 European countries, recruited via validated consumer panels. Results: Overall, 91% of respondents considered their asthma to be 'well controlled', and 92% were confident in their ability to manage it; the majority were not concerned about their asthma (75%) and did not regard their symptoms as serious (72%). However, of those who perceived their asthma to be controlled, 42% had uncontrolled asthma and 37% had partially controlled asthma as defined by the GINA guidelines. Notably, in the 7 days before completing the survey, 42% of respondents with perceived control used their reliever inhaler >3 times, 53% had awoken due to asthma on >1
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PRIMARY CARE RESPIRATORY JOURNAL www.thepcrj.org day and 56% had symptoms that interfered with their normal activities on >1 day. Moreover, many respondents with perceived control had required oral steroids for asthma (43%) or been admitted to AandE (22%) due to their asthma in the previous year. Conclusion: There remains a marked discrepancy between patient-perceived and GINA-defined asthma control; many patients do not associate symptoms with poor control. This suggests a need for initiatives to help patients recognize and respond actively to symptoms to improve their asthma management. University of Groningen, Groningen, Netherlands, 2 Education for Health, Warwick, 3 
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University of Aberdeen, Aberdeen, United Kingdom
Aim: Patient attitudes towards asthma vary and this may impact on disease management. This analysis was designed to group respondents to a large European survey into clusters based on their attitudes towards asthma and its management. Methods: Online surveys were completed by 8000 patients with asthma (aged 18-50 years, >2 prescriptions in the last 2 years) from 11 countries. Cluster analysis was used to identify different clusters of patients based on attitudes towards asthma. Results: Four clusters were identified. Clusters 1 and 2 were defined by a high level of confidence in managing their asthma, and low levels of concern about the disease. Cluster 1 was more adherent to therapy and less likely to ignore HCP instructions than Cluster 2. Clusters 3 and 4 were more concerned about their asthma and considered it serious, and wanted to improve their disease management; these clusters had the lowest levels of GINA-defined control. Cluster 4 was less adherent to therapy and more likely to ignore HCP instructions than Cluster 3. Cluster 4 was most likely to seek additional information about asthma.
Image:
Cluster 1 Results: The most common adverse events (AE) were nasopharyngitis (19.6%), pharyngitis (10.7%), rhinitis (8.2%), bronchitis and headache (both 7.1%). No drug-related serious AEs were reported. The incidence of severe exacerbations (asthma deterioration requiring additional therapy [e.g. systemic steroids], or AandE visit or hospitalization) was low (2.1%, n=6); mean time to onset of severe exacerbation was 237 days (range, 37-413) . Increases from baseline in FEV 1, FEV1 % predicted and forced vital capacity (FVC) were observed at every assessment time point from day 1; these improvements were sustained over 60 weeks (Table) FLUT/FORM vs FLUT and FORM administered concurrently (FLUT+FORM) . This is a post hoc analysis comparing the efficacy of FLUT/FORM 500/20µg with 100/10µg by baseline asthma severity. Methods: 620 patients were randomised 1:1:1:1 to receive FLUT/FORM 500/20µg, 100/10µg, FLUT+FORM 500µg+24µg or FLUT 500µg (all bid), stratified by % predicted FEV 1 at baseline [>40-<60%: severe asthma, 52% patients, vs >60%-<80%: moderate asthma, 48% patients], to allow a post hoc analysis of spirometric and symptom-based endpoints. Results: No dose-response was found between FLUT/FORM 500/20µg and 100/10µg for spirometric variables overall or in either group. Almost all symptom-based endpoints showed treatment effect differences between the doses (in favour of the high dose; more so in the severe asthma group), e.g. changes in mean symptom and mean sleep disturbance scores, % symptomfree and % rescue medication-free days, awakening free nights, % asthma control days, AQLQ score and asthma exacerbations. Aim: The effectiveness of asthma self-management (SM) is well recognised and is a core guideline recommendation. To inform practical implementation of such interventions, we planned to synthesise the findings of systematic reviews to provide a high-level overview. Methods: We searched systematically and screened results from 7 electronic databases, and performed snowball and manual searches. Outcomes of interest included measures of asthma control and asthma-related quality of life. We investigated the composition, delivery, and setting of interventions in order to identify the optimal configuration of asthma SM support. Results: 18 systematic reviews were identified for inclusion, published between 1995 and 2012 and collectively representing 157 randomised controlled trials. The interventions were diverse, targeting healthcare professionals, patients and/or caregivers, as well as being tailored to specific populations by age or ethnicity. Contexts varied, including traditional healthcare settings as well as school-based, home-based, and remote delivery through computerized programmes. Targeting of interventions is important: e.g. paediatric programmes reported significant reductions in asthma morbidity; culturally specific programmes improved asthma related quality of life; and interventions delivered post-asthma related admission reduced risk of future emergency presentation. Conclusion: When implementing asthma SM support it is essential to consider not only the content of the intervention, but also the most appropriate delivery mode and setting for the target population, and the wider healthcare context. Aim: To compare the self-reported causes and extent of activity limitations imposed by pain in Canadians with or without self-reported COPD. Methods: Using data from a national post-census population survey of Canadians reporting participation or activity limitations, we compared the selfreported causes of activity limitations in people with and without COPD using the eight attributes of the Health Utility Index. COPD was considered present if there was a self-report of COPD, emphysema, or bronchitis as the cause of disability. Analyses were weighted to the population. Results: The sample represented 4,219,480 adults, of whom 47,560 (1.1%) reported a diagnosis of COPD. Mobility, agility and pain were the most frequently reported causes of activity limitations for those with or without COPD. Higher proportions of people with COPD than without COPD reported disability caused by problems with: mobility (93.5% vs. 52.6%); agility (82.2% vs. 50.9%) and pain (73.4% vs. 54.8%). Activity limitations attributed to pain occurred for 48.0% of respondents with COPD, compared to 36.8% without COPD. Pain prevented most activities for 21.2% of those with COPD compared to 10.1% of those without COPD. 
University Of Fukui, Fukui, Japan
Aim: The aim of this study was to clarify the nurses' knowledge about COPD and intention to study the disease. Methods: 1) Ethical Issues: The research methods were approved by the Ethical Review Committee of the University of Fukui, Department of Medical Sciences (Approval #23-109). 2) Subjects: The self-oriented questionnaire was distributed to 1505 nurses in 14 hospitals in Japan. 3) Date collection: The questionnaire contained 1) demographic data, and smoking status, 2) knowledge about COPD, 3) frequency of studying COPD and 4) intention to study COPD. Results: 1285 (85.4%) out of 1505 subjects responded to the questionnaire and 1018 (67.6%) were valid data. The data from 744 (49.4%) nurses was analyzed as valid data in this study. The average age was 35.0±9.7 years, and 696 (93.5%) were female. The average year of nursing experience was 12.4±9.4 years. About 544 (73.1%) subjects were non-smokers, 101 (13.6%) were smokers and 99 (13.3%) were ex-smokers. Most of the subjects stated that they knew COPD very well or moderately, and that their body of the knowledge came from basic nursing education. Many subjects responded that efficient medical diagnosis tests for COPD were #1 "spirometry test" (n=497, 96.5%), #2 "chest X-ray" (n=383, 74.4%) and #3 "arterial blood gas analysis" (n=381, 74.0%). However, only 65 (12.6%) subjects pointed out "pulmonary exercise test" as a diagnostic test. It is important to enhance the nurses' knowledge about diagnostic tests, such as pulmonary exercise tests.
Conclusion: It became clear that the nurses didn't have sufficient knowledge
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about COPD diagnostic tests although they thought they had high knowledge about COPD. In order to facilitate early diagnosis of COPD, it is important to promote nurses' as well as ordinary population's knowledge about COPD. 
Disclosure of Interest: None declared
IPCRG13-1095 ONCE-DAILY QVA149 REDUCES EXACERBATIONS, IMPROVES LUNG FUNCTION AND HEALTH STATUS VERSUS GLYCOPYRRONIUM AND TIOTROPIUM IN SEVERE-TO-VERY SEVERE COPD PATIENTS: THE SPARK STUDY
Department of General Practice, CAPHRI, Maastricht University, Maastricht, Netherlands
Aim: To investigate the antibiotic and oral corticosteroid prescribing rate in patients with acute exacerbations of COPD and asthma in general practice, and to identify predictors for antibiotic and corticosteroid prescribing. Methods: 380 patients participated in baseline registrations. The patients were asked to visit their GP during exacerbations the following 12 months. At these visits, the GP registered symptoms, chest findings, pulse oxymetri and CRP. Results: Out of the included patients, 99 patients visited their GP due to one or more exacerbations. Antibiotics were prescribed at the first consultation in 24.2% and systemic corticosteroids in 38.4%. 42.5% of patients with FEV 1 /FVC < 0.7 at baseline were treated with antibiotics compared to 12.3% among patients with FEV 1 /FVC > 0.7 (p=0.001). A similar tendency was shown in prescribing systemic corticosteroids (p=0.007). The antibiotic prescription rate increased with increasing symptoms from 14.1% in patients with Anthonisen type 3 to 30.8% in type 1 (p=0.4). Wheezes/rhonchi predicted the prescribing of both with p-value of 0.004 and 0.003 respectively. Among the patients with CRP > 8mg/L, 48.4% were treated with antibiotics compared to 14.5% among those with CRP < 8 (p=0.001), whereas the CRP value did not significantly predict the prescribing of systemic corticosteroids. Both the prescribing of antibiotic and systemic corticosteroids were significantly associated with oxygen saturation below 93% (p-value 0.01 and 0.02 respectively). Conclusion: Patients with COPD were treated with antibiotics and systemic corticosteroids more often within our cohort. Chest findings and biomarkers were stronger predictors of prescribing of antibiotics and systemic corticosteroids than were the Anthonisen criteria. 
Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, Netherlands
Aim: COPD treatment strategies were traditionally based on lung function impairment alone. In the GOLD 2013 guidelines health status is incorporated as measurement of severity and with that as a disease management modulator. There is no evidence that management based on health status is superior. The aim of the current study is pilot testing this hypothesis. Methods: We enrolled 53 COPD patients in a single blind randomized controlled pilot trial. GPs of patients in both groups received specific predefined treatment advice, based on either health status (measured by the Clinical COPD Questionnaire, health status group: HG) or regular GOLD 2009 based care (control group: CG). This included: diagnosed COPD, >10 pack years. Excluded: asthma, severe co-morbidities, and regular oxygen use. Three visits in 6 months were completed. Each visit encompassed spirometry and questionnaires (disease specific health status (St. George's Respiratory Questionnaire (SGRQ)). The primary outcome was change in SGRQ after 6 months. Univariate analyses were performed using the Mann-Whitney U test. Results: Twenty-eight patients were randomized to CG, and 25 to HG. 58% were male; mean 64yrs and 40 packyrs; GOLD I 38%, GOLD II 57%, GOLD III 6%. SGRQ changed 0,74 in HG and 3,4 in CG (ns). Treatment advice was implemented by the GP in 78,8 % of cases. Conclusion: This pilot study showed no beneficial effect of 6 months treatment based on health status, possibly due to low numbers, but proved that health status based advice for treatment of COPD was acceptable to the GP. A much larger further-developed follow-up study will show if these advice are also beneficial for patients. A PICOS search strategy was used to identify systematic reviews of RCTs reporting interventions promoting aspects of SM for COPD in any healthcare setting. Citations were screened against inclusion criteria, quality assessed and data extracted. Results: 6,435 citations were found and 5 reviews were included (reviews published 2005 -2012 RCTs published 1987 RCTs published -2011 . One review focused specifically on SM interventions, two on education, one on action plans and one on outreach nursing. The SM interventions included a wide range of components (education, self-help, therapy, action plans, group sessions, exercise, relaxation, imagery, smoking cessation, inhaler use) and were delivered within diverse healthcare contexts (integrated care, diseasemanagement, telehealthcare, home care, oxygen therapy services). Review conclusions varied: one found that action plans improved reaction to exacerbations with no significant effect on admissions; one reported that SM education reduced hospital admissions. Lack of detail meant that is was often not clear which component of the heterogeneous interventions were, or were not, effective.
Conclusion:
The lack of clear definitions, the heterogeneity of COPD SM RCTs and the paucity of RCTs examining specific components of SM in COPD, mean that we cannot yet answer our review question. Further high quality research is needed to define the nature of effective SM for COPD and the context in which it should be delivered. Aim: Despite falling prevalence of smoking in developed countries, tobacco use remains one of the major preventable causes of death and illness. General practice interventions to support smoking cessation can be effective but are often underutilised. New models, such as practice nurse (PN) involvement, are needed of enhanced cessation support in primary care. Methods: A three-arm cluster RCT compared support provided by the PN with Quitline referral and with usual GP care. PNs in the Quit with PN arm undertook 6 hours of education and were then supported by mentoring phone calls. Participants were recruited in the practice by trained research assistants. All study participants were offered free nicotine patches. Outcome assessment was by computer assisted telephone interview conducted by research staff blind to group allocation. Primary outcome measures were selfreported sustained and point prevalence abstinence at three month and 12-month follow up points. Results: A total of 101 practices and 2390 patients took part in the study. The loss to follow-up at 12 months was 17.6%. Assuming all those lost to followup have relapsed the sustained abstinence rate at three months for all participants was 7.7% and at 12 months was 4.4%. The point prevalence abstinence at three months was 15.2% and at 12 months was 17.5%.
IPCRG13-1101 ONCE-DAILY GLYCOPYRRONIUM IMPROVES LUNG FUNCTION AND REDUCES EXACERBATIONS IN PATIENTS WITH COPD: A POOLED ANALYSIS OF THE GLOW1 AND GLOW2 STUDIES
Conclusion:
The results show substantial point prevalence cessation rates across all three arms of the study. Multilevel regression analysis is being conducted to examine differences between intervention groups. Aim: Smoking is a common reason for poor asthma control, and associated with corticosteroid resistance, yet smokers are usually excluded from asthma trials. This study investigates the effect of stepping up inhaled corticosteroid (ICS) dose for smokers, non-smokers and ex-smokers. Methods: Retrospective study using the UK Clinical Practice and Optimum Patient Care Research Databases. Adult patients (>30 years) stepped-up their existing ICS (>50% increase in dose) as either EF HFA-BDP or FP. Patients were required to have >2 prescriptions for ICS during both the year prior to and following step-up, and/or a diagnostic code for asthma. Smoking status was defined by database codes, with ex-smokers first recorded as ex-smokers over age 30. EF HFA-BDP patients (step-up year post 2005) were matched 1:1 to FP patients on demographic, disease and smoking characteristics in the baseline year. Exacerbation rates (asthma-related inpatient admissions; emergency room attendances; or use of acute oral steroids) were calculated for outcome year and adjusted for baseline confounders. Modeling explored interactions between treatment effects and smoking status. Results: Median (IQR) doses (mcg) at step-up were 400 (200, 400) for EF HFA-BDP and 500 (500,1000) for FP. Exacerbation rates were comparable for nonsmokers with rate ratio (95% CI) 0.84 (0.68, 1.03) for EF HFA-BDP compared with FP; n=575 per treatment arm, but significantly lower for EF HFA-BDP for current and ex-smokers 0.64 (0.48, 0.85); n=314. Conclusion: Results suggest a differential treatment effect between exsmokers/smokers and non-smokers. It is likely that the smaller particle formulation of EF HFA-BDP plays some role in this effect. Aim: Patients and doctors opinion on the COPD status and management are rarely assessed. This study aimed to find out levels of agreement and satisfaction on COPD prognosis between doctors and patients. Methods: A total of 544 stable COPD patients from Greece were assessed through a cross-sectional study. Patients' demographic data, previous PRIMARY CARE RESPIRATORY JOURNAL www.thepcrj.org A9 treatment, lung function testing and co-morbidity were recorded. Every patient and doctor completed an additional questionnaire respectively regarding satisfaction issues. Descriptive were estimated as well as chi-square test, which was applied on variables regarding the patients' and doctors satisfaction about the disease. Results: An agreement between patients and doctors was found in most of the answers. Agreement was found in 31.5% of the answers on issues as: enough worries about the disease's status. 53.1% of the doctors believed that their patients' disease status could be improved while the 39.4% of the patients shared the same opinion. Only, 13.7% of the doctors and 6.8% of the patients thought that the disease's status couldn't be improved in the future. Conclusion: Patients' and doctors' opinions about the prognosis of the disease were significantly similar, with the doctors being more positive regarding possible disease improvement. Finally, most patients gave answers of medium or high levels of satisfaction referring to the way of coping with their disease. 
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IPCRG13-1103 COMPARATIVE EFFECTIVENESS OF EXTRAFINE HYDROFLUOROALKANE BECLOMETASONE (EF HFA-BDP) AND FLUTICASONE PROPIONATE (FP) IN SMOKING ASTHMATIC PATIENTS -A RETROSPECTIVE, REAL-LIFE OBSERVATIONAL
IPCRG13-1105 PATIENTS' AND DOCTORS' OPINION ABOUT THE DISEASE PROGNOSIS IN STABLE COPD PATIENTS IN GREECE
University of Edinburgh, Edinburgh, United Kingdom
Aim: Asthma self-management is widely recommended by guidelines but poorly implemented. Medical Research Council (MRC) Phase IV studies which accommodate the diversity of patient, professional and healthcare contexts in order to inform implementation in real-life settings are relatively uncommon. We undertook a systematic review of implementation studies of asthma selfmanagement support interventions to explore what works for whom and why. Methods: We searched and screened records from 7 electronic databases, and performed snowball and manual searches. We quality assessed all eligible papers, and extracted and synthesised data. Outcomes of interest included asthma-related symptoms and use of health services. Results: 14 studies were included in the review. The healthcare contexts included primary, secondary, community and private care settings and targeted children/adults. Strategies encompassed one-to-one, telephone or group interventions and/or professional training. Physician only targeted interventions increased the number of action plans and medication prescription but did not appear to influence patient outcomes. Improved patient outcomes, including reduced health services and costs and enhanced QoL, were observed with one-to-one SM interventions delivered either by telephone or face-to-face. During these interventions clinicians provided asthma education, and discussed the management of exacerbations, action plans, and medication and reviewed inhaler technique. Conclusion: Simply training physicians around SM support is insufficient to influence patient outcomes. Healthcare contexts and culture need to be adapted to allocate specific time, resources and processes to enable specific to asthma SM support. Aim: In Sweden nurse based asthma/COPD clinics in primary care are common. However, the organisation looks different even in the same region. There are national, regional and international guidelines for treatment of asthma. In the national guidelines for an asthma/COPD clinic allocated time for the nurse is highlighted. There is still insufficient evidence of the impact of asthma/COPD clinics on asthma control. The aim of this study was to evaluate the effect of nurse based asthma/COPD clinics in primary care on asthma control. Methods: In 2011 every primary health care center (n=25) in the region of Sormland answered a questionnaire about the organisation of care to asthma patients. Two groups with 160 patients each were randomly selected to answer a questionnaire in 2012. One group with patients from five primary health care centres (PHCC) which had asthma/COPD clinics with 0.9 to 2.0 hours/week and 1000 patients (Group A). The other group with patients from PHCC without an asthma/COPD clinic or with < 0.6 hours/week (Group B). Asthma Control Test (ACT) was included in the questionnaire. Results: Of all 25 centres 76 % had an asthma/COPD clinic. Mean allocated time for the nurse was 0.9 hours/week and 1000 patients. The questionnaire was completed by 179 patients (56%), mean age 52.3 years (range 19-75), 56% women. Of patients from centres from an asthma/COPD clinic (group A) 58% had asthma control (ACT >19) compared with 36% of the patients from centres without an asthma/COPD clinic (group B) (p=0.005). Mean ACT in group A was 19.6 and in group B 16.9 (<0.001). Aim: The aim of this study was to investigate whether there is any relationship between working in the rubber industry and having respiratory symptoms. Methods: The study was carried out on the 256 workers exposed to dust at the rubber factory. Spirometry (FVC, FEV 1) was performed on 16 workers with moderate exposure and 240 Workers with high exposure. Information on occupational history, duration of exposure, smoking habits, alcohol consumption, respiratory symptoms (breathlessness, cough and rhinitis) and self reported symptoms with disease were collected. By employing multiple linear regression modeling the potentially confounding effects of age, sex and body mass index were also incorporated into the analysis. Odds ratio were calculated for FVC<80% predicted in different exposure subgroups. Results: Statistically significant reduction in FVC, FEV 1 and PEFR were found when compared to age, small airway obstruction, and also in shortness of breath. Small airway obstructions were found in dust fume (27.2%), smoking (30.3%), alcohol (29.3%). Lung function indices were found to be reduced with increasing duration of exposure to the working environment. The FVC of the workers exposed to factory had a mean of 3.6 ± 0.6. The FEV 1 for workers exposed had a mean of 2.4 ± 0.6. The mean value of the ratio of FEV 1/FVC in exposed workers was 76.8 ± 8.2: there was no statistical difference between these two means. Conclusion: Due to high ambient dust concentration and the observed adverse effects on lung functions worker exposed to dust have more respiratory symptoms and a grater risk of airflow obstruction. A reduction of dust exposure and secondary preventive measure is advised.
Conclusion
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hospital to home affect patient outcomes, is to describe COPD patients' stories of the care transition experience following acute care hospitalizations for AECOPD. Methods: The study's ethnographic design and structural narrative analysis process allowed for focused examination of 26 patients' and 12 family carers' experiences of care transitions. Over 600 stories were identified. All participants shared compelling stories about the transition process from hospital to home within the context of the initial diagnoses of chronic lung disease, hospital experiences for acute exacerbation events, and the ongoing necessity of self-medication management. Results: The patient and family carer stories of navigating a reality of illness characterized by frequent transitions between acute care and home revealed a complex interplay of uncertainty, struggle, and/or resignation. Understanding the experiences of individuals living with COPD during the transition between hospital and home offered opportunities to develop strategies to facilitate the patients' passage through significant care transitions within the continuum of care. Conclusion: Care transitions to home are frequently chaotic and do not account for the individual's ability to manage at home, where supports may be minimal and feel precarious to the patient and caregiver. Aim: To determine if pain and pain interference are associated with comorbidities in people with COPD and secondly, to determine if specific types of co-morbidities are associated with more pain and a particular location of pain. Methods: Patients with moderate to severe COPD were recruited to perform a mail survey that included: the McGill Pain Questionnaire (MPQ), the Brief Pain Inventory (BPI), and a form to list co-morbidities and medications. The MPQ and BPI provide measures of pain intensity and the BPI provides a measure of pain interference and indicates pain locations using a body diagram. Results: A 72% response rate was achieved in return of survey questionnaires. Of 54 COPD patients (FEV 1 48.3±18.2% predicted; 72 years), 44 reported pain. On the BPI, 81% of COPD patients self-reported pain, of whom 66% had moderate to very severe pain and 73% had moderate to very high pain interference with daily activities. In those who experienced pain, 73% reported >2 co-morbidities and 46% reported >3 co-morbidities. Cardiovascular (29%) and musculoskeletal disorders (20%) were the most common co-morbidities followed by endocrine disorders. Those with musculoskeletal or endocrine disorders reported higher levels of pain compared to COPD patients without these types of conditions. COPD patients with musculoskeletal disorders tended to have more pain in the lower extremities and trunk. Pain treatments were used by 64% of patients; acetaminophen and ibuprophen were most common followed by prescription non-steroidal anti-inflammatory and narcotic medications. Conclusion: Significant pain and multiple comorbid conditions are common in people with COPD. Pain associated with comorbid conditions likely compromises full participation in rehabilitation and physical activity in some people with COPD.
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IPCRG13-1116 THE CONTROL OF ALLERGIC RHINITIS AND ASTHMA TEST: VALIDATION OF THE DUTCH VERSION S. van der Leeuw
Aim: The Control of Allergic Rhinitis and Asthma Test (CARAT) was developed to monitor the control of both asthma and allergic rhinitis in primary and secondary care. The objective of this study was to evaluate the psychometric properties of the Dutch version of the CARAT. Methods: The study consists of three measurements with one month intervals. Patients (n=176) diagnosed with asthma and/or rhinitis from three primary and three secondary care centers were approached. Cronbach's · was used to evaluate internal consistency. CARAT scores were compared to the Asthma Control Questionnaire (ACQ) and VAS scores on airway symptoms. Spearman's correlation coefficients were used to determine construct and longitudinal validity. Delta scores of the CARAT, ACQ and VAS were analyzed. Test-retest reliability and Minimal Important Difference (MID) were evaluated using Global Rating of Change (GRC) scores to define categories according to change in symptoms. Results: A total of 93 patients were included. Cronbach's · was 0.82. Correlation coefficients between CARAT and the ACQ and VAS questions ranged from 0.64(p<0.01) to 0.76(p<0.01). Longitudinally, correlation coefficients between delta CARAT scores and delta ACQ and VAS ranged from 0.41 to 0.67(p<0.01) for both one month intervals. Calculations for test-retest reliability showed ICC's of 0.74(p<0.01) and 0.78(p<0.01) between CARAT scores of stable patients. The MID for the CARAT was 3.50.
Conclusion:
The Dutch CARAT is a valid and reliable tool for use in clinical research and practice to monitor asthma and allergic rhinitis symptoms simultaneously.
Disclosure of Interest: None declared
IPCRG13-1117 PATIENTS' DESCRIPTIONS OF LIVING WITH COPD IN VARIOUS STAGES OF THE ILLNESS
E. Österlund Efraimsson 1 1
School of Health and Social Studies, Dalarna University, Falun, Sweden
Aim: To explore which problems patients with COPD in all four stages express and describe during visits at nurse-led COPD clinics in primary health care. Methods: A prospective qualitative observational study comprising two videotaped consultations, first and third re-visit, with each of 20 patients (13 women), all smokers (n=11) or former smokers diagnosed with COPD. The consultations were conducted by six COPD-nurses in primary health care and analysed byqualitative content analysis. Results: Smokers wished to quit smoking but expressed motivational difficulties in fighting cravings. Concerns about the visits were mainly about the spirometry examination, which they found exhausting and difficult to perform. Also, they expressed that they were worried about the results. Other concerns included the prospect of increasing symptoms and fears about future health. Symptoms described in all stages were cough, phlegm and shortness of breath connected even with light physical exertion. In stage III and IV, dyspnea was the most severe symptom affecting daily activities. Patients expressed concern about symptoms that could be dangerous or fatal. Previously independent activities necessitated planning and help from others. They wished to learn about self -management and used various strategies to handle their disease even when offered support and assistance. Patients told that information about COPD, how to handle symptoms and treatment in daily life increased their security and control. Conclusion: Patients were concerned about their smoking habits and subsequent symptoms being dangerous or fatal. Shortness of breath was troublesome and limited everyday life already in early stages of COPD, thus not always correlated to the severity of the disease. MRT regimen: 80/4.5µg, n=119; 160/4.5µg, n=3106; 2x160/4.5µg, n=1355) with diary data (median exposure 344 days). Respective median (mean) B/F inh. use in patients prescribed MRT 80/4.5µg, 160/4.5µg, 2x160/4.5µg was: total maintenance + as-needed use 2.11(2.48), 2.14(2.53) and 4.05(4.27) inh./24h; total daily B doses 169(198), 342(405) and 648(683)µg. As-needed use was higher with higher-maintenance dose 0.17(0.68), 0.26(0.73) and 0.45(1.08) inh./24h, respectively. As-needed-free (maintenance-only) days/yr were higher with lower maintenance dose 242(66.3%), 231(63.2%) and 224(61.4%), respectively. Days/yr with high asneeded use (>4 inh./day) were lower with lower maintenance dose: 1.5(0.4%), 4.3(1.2%) and 9.0(2.5%), respectively. Conclusion: As-needed use is low irrespective of Symbicort SMART™ regimen. High levels of asthma control were suggested by high percentages of reliever-free and low incidence of high-reliever-use days in all Symbicort SMART™ regimens. 
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ICS/LABA combinations: F/S or BUD/FM. Methods: In this observational, retrospective, matched-cohort study (NCT01146392), Swedish medical records data (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) ) from COPD pts were linked to hospital, drug and cause-of-death registry data. Pair-wise (1:1) propensity score matching was performed at index date (first prescription post-COPD diagnosis). This factorial analysis examined the influence of treatment, disease burden and ICS dose on pneumonia outcomes. Results: A 73% higher rate of pneumonia was observed with F/S (n=2734) vs. BUD/FM (n=2734) treatment (11.0 vs. 6.4 events/100 pt-years; rate ratio 1.73 [95% confidence interval (CI): 1.57-1.90], p<0.001). Fatal pneumonia events were more frequent with F/S (97 deaths [3.54%]) than BUD/FM (52 deaths [1.90%]; hazard ratio 1.76; 95% CI 1.22-2.53; p=0.0025) and intra-class treatment differences increased disproportionately in pts with a higher disease burden, while the effect of ICS dose was less pronounced. The annual rate of pneumonia with F/S depended on both dose and overall disease burden, but this relationship was weaker for BUD/FM. Conclusion: COPD pts treated with BUD/FM experienced significantly fewer pneumonia events, including fatal pneumonia, than pts treated with F/S. Fatal pneumonia event rates were influenced more by ICS/LABA type and baseline burden of disease than ICS dose. Methods: 4022 SAR patients (>12 years old) were randomized to 14 days treatment with MP29-02 † , AZE, FP or PLA nasal sprays (1 spray/nostril bid). 612 chronic rhinitis patients (>12 years old) were randomized to 1yr, openlabel treatment with MP29-02 † (1 spray/nostril bid) or FP (2 sprays/nostril qd). Safety was assessed by incidence, type, and severity of adverse events, vital signs and nasal examination. Results: Treatment-related adverse events (TRAEs) were those usually reported with AZE (dysgeusia) and FP (headache and epistaxis), often did not exceed PLA (Table) and were 'mild' in most cases. Long-term, there was no evidence of accumulation of TRAEs over time, any occurrence of late AEs and none were considered severe. <3% of subjects discontinued from the study due to an AE. A SAE was reported by 3 MP29-02 subjects and 1 FP subject, but none was considered treatment-related. MP4002 SAR study (14 days Aim: To investigate the long-term effects of a multidisciplinary program of pulmonary rehabilitation (PR) on functional capacity, quality of life (QoL) and exacerbation frequency among patients with COPD in primary health care (PHC). Methods: The study had a quasi-experimental design. Patients with COPD in GOLD stage 2 and 3 were included, 49 in the intervention group and 54 in the control group. The intervention consisted of PR containing a program over six weeks. At baseline, after one and three year the functional capacity was assessed with 6-minutes-walking-test (6MWT) and QoL was assessed with Clinical COPD Questionnaire (CCQ). Exacerbation frequency was calculated one year before the programme until three years after. Results: No significant differences between the groups were shown in 6MWT and CCQ after one year or three years. Participants within both groups increased their 6MWT with statistical significance (p=0.004) and (p=0.002) from baseline to the one-year follow-up but no significances between baseline and after three years. The patients within the intervention group increased their QoL after one year (p=0.022) but no change was found within the control group (p=0.086). No significances between baseline and three years follow up within both groups. The exacerbation frequency decreased in the intervention group and increased in the control group (p=0.009) after one year but did not persist over a three-year period. Aim: Sub-lingual immunotherapy (S.L.I.T.) Rush immunotherapy was tried on some patients to evolve some faster and affordable immunotherapy modality to make the patient achieve the maintenance plateau within a very short time. Conventional method of immunotherapy is administered with long durations; rush immunotherapy is a super-fast methodology in attaining the maintenance/boosting module, which requires hospitalization and other precautionary methods, and multiple allergen vaccines to be administered within short span of time. But in this method, it has been found that within 15-20 days the relief of the immunotherapy can be reached. Methods: 186 patients out of which 48 with urticaria allergy and 138 with allergic rhinitis and bronchial asthma were selected. The therapy consists of administration of four vials of allergen extracts, 1st vial: 1:25,00, 2nd vial 1:2,50, 3rd vial 1:25, and 4th vial 1:10 dil. The 1st and the 2nd concentrations were administered in daily 6-hourly schedules in a graphically rising manner. The patients had been given pre-medication. Blood examination and IgG and IgE level estimation were done before and after 8 weeks. Results: Some of the patients showed local skin reactions, which subsided without drugs, and no systemic reaction was noted. Aim: To explore the co-morbid conditions associated with asthma in a large, nationwide, one-day point prevalence, cross-sectional study in India. Methods: 12,000 primary care physicians from 880 cities and towns were randomly selected and invited to participate in this one-day point prevalence study. On 1st Feb '11 all participating doctors captured presenting symptoms and diagnosis of all patients who visited them. Clean data transferred into the EPI INFO software was analyzed for associations between Asthma and other co-morbid conditions, using chi-square test. Results: 7,400 doctors consented and provided clean data of 204,912 patients (M: 54.1%; F: 45.9%). 10595 (5.2%) patients were reported to have Asthma. Data on strong association found between Cataract and Asthma is being presented as a separate abstract at this meeting. The table shows association between Asthma and other co morbid conditions: Aim: The study is designed to determine the pattern and percentage of presentation of different grades of COPD patients in a primary care respiratory centre.
Methods: This is a prospective study done in a well-established and busy primary care respiratory centre in Khulna; one of the largest cities of Bangladesh. Data was collected within the time duration of 25th February 2012 to 10th of March 2013.The source of data was an electronically-updated database. A total of 802 patients were included in the study all of whom visited the centre during this period. Among them 664 (82.8%) were male and 138 (17.2%) were female. All the patients were attended initially according to their priority and followed up there after. Most of the patients were treated on domiciliary basis while few requiring hospital admission. The age range of the patients was 31-100 years. The patients were included on the basis of clinical history; examination and diagnosis were confirmed by spirometry (as per GOLD criteria). Results: Among the total patient (802) population, 53 patients were COPD-1 (6.6%); 153 COPD-2 (19.07%), 322 COPD-3 (40.14%) and 274 patients with COPD-4 (34.16%). 82.8% were male and 17.2% were female. Most of the female patients seek help in their grade 4 stage. Female patients are mostly non-smokers; their risk factor is biomass fume exposure in the kitchen. Conclusion: COPD is a preventable and treatable disease. As such early detection and appropriate intervention will decrease the suffering of the patient and burden of COPD. A more structured nationwide study is necessary for further evaluation of the situation. 
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interesting items for the assessment of control of asthma. The formal consensus process was carried out in two rounds of experts' contribution with feedback after each round. A web form tool was used in this process. In both rounds 155 primary care and 64 secondary care physicians were invited to participate. In the second round the options to answer the questions were defined. The items were further divided into 3 sections to simplify the software development -patient background, consultation registry and consultation support. Results: The initial study identified 29 potentially interesting items, divided into 3 sections -13 items related to patient background, 8 items related to the consultation registry and 8 items related to the consultation support. The first round of experts' contribution had the participation of 92 primary care and 36 secondary care physicians; the second round had in total 79 participants. After the two rounds the questions and answer options were formulated. Some items were also excluded -3 from the patient background and 2 from the consultation support. All the steps of the consensus process were completed in 4 months. Conclusion: A tool to measure the control of asthma was developed with the support of a methodology that ensured its quality and validity. A study has now started that aims to evaluate the clinical control of a population of asthma patients using this tool. 
Dalarna county council -Central administration, Division of Medicine, Falun, Sweden
Aim: To describe the contact patients had with primary health care retrospectively a year before lung cancer was diagnosed: number of contacts, specific symptoms of lung cancer and time from the first contact until referral to chest x-ray, specialized lung clinic and diagnosis. Methods: The design was a retrospective medical record review with a quantitative approach. Ten records were selected from patients diagnosed with lung cancer in a mid-Swedish municipality from January to June 2011. Results: Patients had on average eight primary health contacts (telephone advice and/or surgery visits) with a registered nurse or doctor the year before a lung cancer diagnosis was established. On average, four of these contacts could be linked with specific symptoms of lung cancer such as cough, dyspnea, fatigue, back/chest pain and hemoptysis. The average time span from the first contact about specific symptoms until diagnosis was 21 weeks. The average time from making a lung cancer clinic referral until establishing a diagnosis was three weeks.
Conclusion:
The study showed a large discrepancy between practice and clinical guidelines on chest x-ray for smokers over 40 experiencing new respiratory symptoms. On average the patient had contact with primary health care showing specific lung cancer symptoms for eleven weeks until a chest xray referral was made and for 21 weeks until a diagnosis was established. Disclosure of Interest: None declared
